Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 4—April 2024
Research Letter

Case Management of Imported Crimean-Congo Hemorrhagic Fever, Senegal, July 2023

Author affiliations: Ministry of Health and Social Action, Dakar, Senegal (Y.B. Gueye, Y. Sall, I. Diagne, K.D. Sow, A. Diallo, P.S. Dièye, J.P. Diallo, B. Diop); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J. Loko Roka, O. Pasi)

Cite This Article

Abstract

We report an imported Crimean-Congo hemorrhagic fever case in Senegal. The patient received PCR confirmation of virus infection 10 days after symptom onset. We identified 46 patient contacts in Senegal; 87.7% were healthcare professionals. Strengthening border crossing and community surveillance systems can help reduce the risks of infectious disease transmission.

Crimean-Congo hemorrhagic fever (CCHF), a severe form of hemorrhagic fever primarily transmitted to humans and animals through tick bites, is caused by CCHF virus (CCHFV). In addition, direct human contact with blood or infected tissues from viremic animals and contact with blood or secretions of an infected person have been described as transmission routes (1,2). In Senegal, the circulation of CCHFV has been reported in humans, livestock, and ticks in different areas of the country (3,4). During March–September 2023, Senegal declared a CCHF outbreak that had 8 cases distributed across 5 regions of the country (5). During July 2023, CCHF was diagnosed in a Senegal hospital for the 4th patient, who resided in another country. We report on the management of this imported CCHF case in Senegal.

The patient was a man in his 50s who was a trader residing in the capital of a country neighboring Senegal. He might have come into close contact with animals through his work or at home. He experienced fever, headache, and abdominal pain 2 days after returning to his rural home on July 16, 2023. The symptoms led to a consultation at a private healthcare facility in his home country, where treatment was initiated without improvement. The persistence of clinical symptoms prompted a consultation at a referral hospital in his country of residence, after which the patient’s health further deteriorated 2 days later. He had petechiae, and an abdominal ultrasound revealed hepatopathy, which prompted a family decision to seek better care in Senegal.

In Senegal, a fibroscopy and biologic tests were conducted, and results showed severe thrombocytopenia at 2,000 platelets/μL (reference range 150,000–450,000/μL). The patient was transferred to a healthcare facility that managed severe clinical cases. Because of a worsening clinical condition, including hyperglycemia and hematemesis, the patient was then transferred to the National Hospital of Pikine, Dakar, and admitted to the intensive care unit. On the 3rd day of intensive care hospitalization, the health district team collected blood samples for biologic analysis. PCR testing was positive for CCHFV 10 days after disease onset, but the patient died from multiorgan failure on the same day that PCR results were obtained.

During the case study, the investigation team identified 38 contacts in the patient’s home country; 46 contacts were identified in Senegal, most (87.7%) healthcare personnel, including doctors, nurses, and laboratory staff. No bloodborne pathogen exposure incidents were reported during patient care or while handling the patient’s samples. However, the level of infection prevention and control (IPC) was relatively low. We assessed the IPC level by using a structured assessment that had questions regarding the availability and usage of personal protective equipment, material sterilization, waste management, and the healthcare personnel’s IPC training.

We observed a delay in diagnosis for this patient despite seeking medical attention at the onset of symptoms. The time between the onset of symptoms and diagnosis was 10 days. In India, a study involving 4 CCHF cases reported an average delay of 5.75 days from symptom onset to diagnosis (6). However, in northern Senegal, a CCHF case was diagnosed within 3 days of symptom onset because the 4S surveillance network, a Senegal surveillance sentinel sites system (4), was deployed. The 4S surveillance system encompasses 25 sentinel sites distributed across the country; >1 site exists in each of the country’s 14 regions.

Healthcare personnel accounted for 87.7% of this patient’s contacts in Senegal. According to reports in the literature, healthcare professionals are one of the socioprofessional categories most affected by secondary CCHF infection (7,8). One study showed that 49% of laboratory-confirmed secondary CCHF cases were among healthcare personnel; needlestick injuries were the primary mode of exposure in 62.7% of those cases (8). In addition, that study identified 21 CCHF cases associated with travel (8). The case we report indicates that countries should adhere to Annex 1 of the World Health Organization’s International Health Regulations that defines the core capacity requirements for detecting ill travelers (9). During management of this CCHF case, we found no documented incidents of blood exposure, and no secondary CCHF cases were reported at the end of the 14-day contact follow-up, despite the relatively low IPC level.

In conclusion, we believe the delay in diagnosing this CCHF case resulted from the patient seeking care at multiple healthcare facilities. The healthcare personnel exposure that we identified highlights the necessity of systematically adhering to standard IPC precautions. Establishing a system for detecting potential epidemic diseases at border crossings, coupled with strengthening community surveillance, can help reduce the risks of infectious disease transmission.

Dr. Gueye is the operation unit chief at the Senegal National Emergency Operation Center within the Ministry of Health and Social Action. His research interests focus on viral infectious diseases transmissible by blood, sickle cell disease, and hemophilia.

Top

Acknowledgment

We thank all of the medical teams across the country for their invaluable commitment to providing health care to their patients.

Top

References

  1. Abudurexiti  A, Adkins  S, Alioto  D, Alkhovsky  SV, Avšič-Županc  T, Ballinger  MJ, et al. Taxonomy of the order Bunyavirales: update 2019. Arch Virol. 2019;164:194965. DOIPubMedGoogle Scholar
  2. Hawman  DW, Feldmann  H. Crimean-Congo haemorrhagic fever virus. Nat Rev Microbiol. 2023;21:46377. DOIPubMedGoogle Scholar
  3. Mhamadi  M, Badji  A, Dieng  I, Gaye  A, Ndiaye  EH, Ndiaye  M, et al. Crimean-Congo hemorrhagic fever virus survey in humans, ticks, and livestock in Agnam (northeastern Senegal) from February 2021 to March 2022. Trop Med Infect Dis. 2022;7:324. DOIPubMedGoogle Scholar
  4. Dieng  I, Barry  MA, Diagne  MM, Diop  B, Ndiaye  M, Faye  M, et al. Detection of Crimean Congo haemorrhagic fever virus in North-eastern Senegal, Bokidiawé 2019. Emerg Microbes Infect. 2020;9:24857. DOIPubMedGoogle Scholar
  5. World Health Organization African Region. Weekly bulletin on outbreaks and other emergencies, week 42, October 16–22, 2023 [cited 2024 Feb 15]. https://iris.who.int/bitstream/handle/10665/373912/OEW42-1622102023.pdf
  6. Tripathi  S, Bhati  R, Gopalakrishnan  M, Bohra  GK, Tiwari  S, Panda  S, et al. Clinical profile and outcome of patients with Crimean Congo haemorrhagic fever: a hospital based observational study from Rajasthan, India. Trans R Soc Trop Med Hyg. 2020;114:6439. DOIPubMedGoogle Scholar
  7. Maltezou  HC, Papa  A, Ventouri  S, Tseki  C, Pervanidou  D, Pavli  A, et al. A case of Crimean-Congo haemorrhagic fever imported in Greece: Contact tracing and management of exposed healthcare workers. J Infect Prev. 2019;20:1718. DOIPubMedGoogle Scholar
  8. Leblebicioglu  H, Sunbul  M, Guner  R, Bodur  H, Bulut  C, Duygu  F, et al. Healthcare-associated Crimean-Congo haemorrhagic fever in Turkey, 2002-2014: a multicentre retrospective cross-sectional study. Clin Microbiol Infect. 2016;22:387.e14. DOIPubMedGoogle Scholar
  9. World Health Organization. International health regulations (2005), 3rd edition [cited 2023 Aug 24]. https://www.who.int/publications/i/item/9789241580496

Top

Cite This Article

DOI: 10.3201/eid3004.231492

Original Publication Date: February 28, 2024

Table of Contents – Volume 30, Number 4—April 2024

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Jerlie Loko Roka, Centers for Disease Control and Prevention, Senegal office, B.P. 49, Rte des Almadies, Dakar, Senegal

Send To

10000 character(s) remaining.

Top

Page created: January 31, 2024
Page updated: March 21, 2024
Page reviewed: March 21, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external